Simcere Pharma (SCR) Misses Street's Q1 Views
More News related to SCR
- 105 of Simcere Pharma's (SCR) Drugs Included on China's Drug Reimbursement List
- Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List
- Simcere Pharma (SCR) Subsidiary Suspends Product for Quality Control Check
- Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production
- Current Investor Affinity for U.S.-Listed China Stocks to be Discussed at IR Magazine's China Conference & Awards
More News related to Earnings
- Raymond James Upgrades Newpark Resources (NR) to Outperform
- Raymond James Upgrades Culp (CFI) to Strong Buy
- Satyam (SAY) Jumps 5% as JPMorgan Issues Intraday Upgrade
- Credit Suisse Upgrades MDC Holdings (MDC) to Neutral, $29 Target
- BMO Capital Upgrades EMCOR Group (EME) to Outperform
Simcere Pharmaceutical Group (NYSE: SCR) reports Q1 EPS of $0.06, 11 cents lower than the analyst estimate of $0.17. Revenue for the quarter was $64.8 million, versus the consensus of $69.87 million.
Related Categories
EarningsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
